Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jozien Helleman

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Cancer Biology & Therapy|June 16, 2006
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporterJozien Helleman, Herman Burger, Irene H L Hamelers, et al.
Histopathology|May 3, 2019
Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimensEva Hollemans, Esther I Verhoef, Chris H Bangma, et al.
Cancers|July 27, 2022
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 CohortCristina Marenghi, Zhuyu Qiu, Jozien Helleman, et al.
Translational Andrology and Urology|April 14, 2021
A first step towards a global nomogram to predict disease progression for men on active surveillanceMieke Van Hemelrijck, Xinge Ji, Jozien Helleman, et al.
The Prostate|March 7, 2022
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium databaseKerri R Beckmann, Chris H Bangma, Jozien Helleman, et al.
BMC Cancer|August 2, 2006
Mismatch repair and treatment resistance in ovarian cancerJozien Helleman, Iris L van Staveren, Winand N M Dinjens, et al.
European Urology Open Science|December 22, 2021
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium DatabaseKerri Beckmann, Aida Santaolalla, Jozien Helleman, et al.
Plos One|July 30, 2011
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinomaXuan Bich Trinh, Wiebren A A Tjalma, Luc Y Dirix, et al.
European Urology|November 3, 2018
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Xi Ji, Jozien Helleman, et al.
European Urology Oncology|October 1, 2019
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen A Kalapara, Jan F M Verbeek, Daan Nieboer, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Cancer Biology & Therapy|June 16, 2006
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporterJozien Helleman, Herman Burger, Irene H L Hamelers, et al.
Histopathology|May 3, 2019
Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimensEva Hollemans, Esther I Verhoef, Chris H Bangma, et al.
Cancers|July 27, 2022
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 CohortCristina Marenghi, Zhuyu Qiu, Jozien Helleman, et al.
Translational Andrology and Urology|April 14, 2021
A first step towards a global nomogram to predict disease progression for men on active surveillanceMieke Van Hemelrijck, Xinge Ji, Jozien Helleman, et al.
The Prostate|March 7, 2022
Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium databaseKerri R Beckmann, Chris H Bangma, Jozien Helleman, et al.
BMC Cancer|August 2, 2006
Mismatch repair and treatment resistance in ovarian cancerJozien Helleman, Iris L van Staveren, Winand N M Dinjens, et al.
European Urology Open Science|December 22, 2021
Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium DatabaseKerri Beckmann, Aida Santaolalla, Jozien Helleman, et al.
Plos One|July 30, 2011
Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinomaXuan Bich Trinh, Wiebren A A Tjalma, Luc Y Dirix, et al.
European Urology|November 3, 2018
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Xi Ji, Jozien Helleman, et al.
European Urology Oncology|October 1, 2019
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen A Kalapara, Jan F M Verbeek, Daan Nieboer, et al.
Pageof 5